Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Chemotherapy-Induced Cardiomyopathy Monica Abraham Intern Mentor Atholton High School Mentor: Lili Barouch, M.D. Johns Hopkins Cardiology Columbia Medical Campus Preview • • • • • • Research Question Anthracyclines Chemotherapy-Induced Cardiomyopathy Risk Factors My Research Conclusion Research Question • Which risk factor makes patients most likely to develop chemotherapy-induced cardiomyopathy? Research Design: Causal-Comparative • Terms: -chemotherapy: the treatment of cancer by the use of chemical substances -cardiomyopathy: the deterioration of the heart muscle -anthracycline: common type of breast cancer chemotherapy drug -myocyte: muscle cell Anthracyclines • Chemotherapy agents • Commonly treat breast cancer and lymphomas • Can cause cardiomyopathy • Myocyte damage • Production of toxic radicals • Increase in oxidative stress • Lipid peroxidation • Vacuolation • Myocyte replacement by fibrous tissue Chemotherapy-Induced Cardiomyopathy • Symptoms • palpitations, shortness of breath, chest pain, fatigue • Acute Cardiovascular Complications • Short-term • Arrythmias • Chronic Cardiotoxicity • Clinical heart failure • May be a link between acute and chronic cardiotoxicity Risk Factors • Cumulative dose • Age • Other cardiotoxic chemotherapy agents • Radiation • History of CVD My Research • Purpose is to identify most prevalent risk factor • Review charts of prior and current patients of Dr. Barouch to study patients’ histories • Be able to ascertain most common risk factor • Patients with that risk factor can then consider their options Conclusion •Certain chemotherapy drugs, such as anthracyclines, damage myocardial function •Cardiomyopathy can result •Important to determine which risk factors are most detrimental •Prevention medication and screening can help reduce risk of cardiomyopathy Works Cited Barouch, Lili. Personal interview. 23 Oct. 2013. Gharib, M. I., and A. K. Burnett. "Chemotherapy-induced Cardiotoxicity: Current Practice and Prospects of Prophylaxis." European Journal of Heart Failure (2002). Oxford Journals. Web. 19 Oct. 2013. Hare, Joshua M. "The Etiologic Basis of Congestive Heart Failure." Atlas of Heart Failure: Cardiac Function and Dysfunction. 3rd ed. 2002. Print. Katz, Arnold M. "Molecular and Cellular Basis of Contraction." Atlas of Heart Failure: Cardiac Function and Dysfunction. Ed. Wilson S. Colucci. 3rd ed. 2002. Print. Singal, Pawan K., and Natasha Iliskovic. "Doxorubicin-Induced Cardiomyopathy." New England Journal of Medicine (1998). Google Scholar. Web. 19 Oct. 2013.